経口タンパク質・ペプチド市場：製品タイプ、製剤、開発フェーズ、用途、エンドユーザー別-2025～2030年世界予測

経口タンパク質・ペプチド市場は、2023年に61億米ドルと評価され、2024年には68億9,000万米ドル、CAGR 13.27%で成長し、2030年には146億米ドルに達すると予測されています。

経口タンパク質と経口ペプチドは、進化する治療の展望の中で、疾病管理と患者のアドヒアランスに変革的な利点を提供する焦点として浮上してきました。近年、バイオテクノロジーと製剤科学の著しい進歩により、これらの分子が従来の投与の壁を越える道が開かれました。バイオアベイラビリティを確保するだけでなく、患者の快適性とコンプライアンスを高める強固な経口投与システムの開発がますます重視されるようになっています。研究の深化と技術の進化に伴い、市場は製薬開発企業、医療プロバイダ、投資家の関心を集めています。

この包括的なレビューでは、市場の現状を詳述するとともに、今後の成長軌道に関する洞察も提供しています。主要動向の把握、革新的な製剤戦略の検討、市場拡大に対する規制枠組みの影響の評価などを行っています。本分析は、急速な技術進歩や、より効果的で患者中心の治療を求める世界の動きが顕著な環境の中で組み立てられています。本論考は、エビデンスによる意思決定と戦略的市場介入へのコミットメントで知られる利害関係者を対象としています。進化する患者のニーズが需要を牽引する中、経口タンパク質・ペプチド市場は、治療のパラダイムを再定義し、治療成果を最適化する破壊的なブレークスルーを迎えます。

戦略的な観点から、本書は貴重な知的ハブとして機能し、市場動向の解明に役立つデータに裏打ちされた洞察と詳細な定性分析を記載しています。提供される洞察は、アンメット・メディカル・ニーズに対応するための臨床的進歩と市場戦略の統合に焦点を当てています。最終的に、これら洞察の統合は、相互に緊密に結びついた市場において、研究、革新、商業化活動を整合させることの重要性を強調し、変革の旅の舞台を設定するものです。

市場情勢の転換とその戦略的意味合い

過去数年間、経口タンパク質とペプチドの市場は、急速な科学的ブレークスルーと世界の医療の優先事項の再編成によって、変革的なシフトを経験してきました。ドラッグデリバリーシステムにおける最近の技術革新は、利便性と有効性を効果的に組み合わせた有望な代替品を導入することで、長年の非経口投与への依存に課題しています。この進化は、患者中心のアプローチ、先端バイオテクノロジー、研究機関と製薬企業との戦略的パートナーシップに改めて焦点が当てられていることに支えられています。

新たなカプセル化技術の登場、ペプチドの安定性の向上、経口吸収促進における改良は、この変革の中心的な要素です。規制当局も画期的な治療に対応できるよう、その枠組みをますます適応させており、それによって承認が早まり、イノベーションを受け入れやすい環境が醸成されています。このような技術的進歩と並行して、市場の利害関係者は、臨床的要件と経済的持続可能性の両方に対応する統合ソリューションの開発へと戦略を方向転換し始めています。意思決定者は現在、予測分析、ビッグデータ、リスクベースのモニタリングを活用し、研究開発パイプラインを合理化すると同時に、市場投入までの時間を最短化しています。

さらに、市場は世界の投資の流れに関して大きな再編成が見られ、新興の治療領域や十分な治療を受けていない患者層を対象とすることに重点が置かれています。その結果、伝統的市場関係者は事業の枠組みを見直し、ダイナミックで柔軟なビジネスモデルを追求せざるを得なくなっています。このシフトは単なる漸進的な改善ではなく、競争戦略を再定義し、臨床における新たな価値提案を形成するパラダイム変化を意味します。このような環境において、こうした変革の恩恵を享受するためには、堅実な調査とシームレスな実行に支えられた先見的なアプローチが不可欠です。

製品開発と市場戦略を形成するセグメンテーションに関する主要な洞察

市場セグメンテーションの微妙な理解が、経口タンパク質・ペプチドセグメントにおける戦略立案と製品開発を支えています。市場は複数の次元に基づいて厳密に分析され、それぞれがその構造と成長の可能性に関する重要な洞察をもたらします。まず、製品タイプ別では、インスリンベースのタンパク質とペプチド治療を区別しています。さらに、このカテゴリーでは、併用インスリン製剤、長時間作用型インスリンアナログ製剤、速効型インスリンアナログ製剤、遺伝子組換えヒトインスリン製剤などのサブセグメントや、カルシトニンベースの治療、グルカゴン様ペプチド-1受容体作動薬、バソプレシンアナログ製剤に対応するセグメントが明らかにされています。この詳細な分割により、治療効果、市場浸透、技術革新動向の深堀りが容易になります。

市場は製剤ベースでも区分され、カプセル製剤、液剤、粉末製剤、錠剤など、さまざまな選択肢があることから、送達形態の重要性が強調されています。これらの剤形は、患者のコンプライアンスと臨床転帰を改善するために継続的に検査され、最適化されています。並行して、開発段階のセグメンテーションは治療の成熟度に関する洞察を提供し、第I相と第II相臨床検査、第III相臨床検査、開発後調査、前臨床検査に分類されます。このセグメンテーションは研究強度を強調するだけでなく、パイプライン製品のリスクプロファイルを特定するのにも役立ちます。

用途ベースのセグメンテーションは、がん治療、心血管疾患、糖尿病管理、ホルモン障害などの特定の治療領域に焦点を当てることで、市場の視点をさらに絞り込みます。このアプローチにより、市場参入、規制遵守、患者エンゲージメントのために、各用途セグメントに合わせた戦略を確実に提供することができます。在宅医療、病院クリニック、研究所、専門クリニックなどのエンドユーザーによるセグメンテーションは、製品のポジショニングを顧客のニーズや業務実態に合致させる上で極めて重要な役割を果たします。こうした様々なセグメンテーションを総合的な分析に統合することで、利害関係者は市場機会をより的確に予測し、臨床イノベーションと商業的実行可能性の間の複雑な相互作用に対処することができます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 革新的な経口タンパク質治療を必要とする慢性疾患の増加
    • 栄養意識の高まりとともに、経口タンパク質とペプチドサプリメントの需要が高まっている
  • 抑制要因
    • 重大な副作用に関する懸念
  • 機会
    • 経口タンパク質療法の進歩に向けた製薬企業とバイオテクノロジー企業の協力関係
    • 大環状ペプチドの開発への新たな焦点
  • 課題
    • 世界中で新しい経口タンパク質治療の承認プロセスに影響を与える規制上のハードル
• 市場セグメンテーション分析
  • 製品タイプ：骨代謝障害と2型糖尿病を標的としたペプチド治療の需要増加
  • 製剤：投与の容易さと敏感な生物学的化合物を保護する能力により、カプセル製剤が好まれるようになっている
  • 開発フェーズ：経口タンパク質・ペプチドにおける発達段階の多様性の探究
  • 用途：患者のコンプライアンスを高めるためのがん治療における経口タンパク質とペプチドの需要の増加
  • エンドユーザー：在宅ケア環境における経口タンパク質とペプチドに対する消費者の嗜好の高まり
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 経口タンパク質・ペプチド市場：製品タイプ別

• イントロダクション
• インスリンベースのタンパク質
  • 複合インスリン製剤
  • 長時間作用型インスリンアナログ
  • 速効型インスリンアナログ
  • 組み換えヒトインスリン
• ペプチド治療法
  • カルシトニンベースの治療法
  • グルカゴン様ペプチド-1受容体作動薬
  • バソプレシン類似体

第7章 経口タンパク質・ペプチド市場：製剤別

• イントロダクション
• カプセル製剤
• 液体製剤
• 粉末製剤
• 錠剤製剤

第8章 経口タンパク質・ペプチド市場：開発フェーズ別

• イントロダクション
• フェーズIとII臨床検査
• フェーズIII臨床検査
• 市販後研究
• 前臨床研究

第9章 経口タンパク質・ペプチド市場：用途別

• イントロダクション
• がん治療
• 心血管疾患
• 糖尿病管理
• ホルモン障害

第10章 経口タンパク質・ペプチド市場：エンドユーザー別

• イントロダクション
• 在宅ケア
• 病院とクリニック
• ラボ
• 専門クリニック

第11章 南北アメリカの経口タンパク質・ペプチド市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋の経口タンパク質・ペプチド市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの経口タンパク質・ペプチド市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Amgen Inc.
• Amryt Pharma plc
• Astellas Pharma Inc.
• AstraZeneca PLC
• Biocon Limited
• Boehringer Ingelheim International GmbH
• Catalent, Inc.
• Entera Bio Ltd. by DNA Biomedical Solutions
• F. Hoffmann-La Roche AG
• Hunan Huateng Pharmaceutical Co., Ltd. by Tasly Capital
• Johnson & Johnson Services, Inc.
• Merck KGaA
• Novartis AG
• Novo Nordisk A/S
• Oramed Pharmaceuticals Inc.
• PeptiDream Inc.
• Pfizer, Inc.
• Protagonist Therapeutics, Inc.
• Proxima Concepts Limited
• Rani Therapeutics, LLC
• Sanofi S.A.
• Tarsa Therapeutics, Inc.
• Teva Pharmaceutical Industries Ltd.
• Zealand Pharma A/S

LIST OF FIGURES

• FIGURE 1. ORAL PROTEINS & PEPTIDES MARKET MULTI-CURRENCY
• FIGURE 2. ORAL PROTEINS & PEPTIDES MARKET MULTI-LANGUAGE
• FIGURE 3. ORAL PROTEINS & PEPTIDES MARKET RESEARCH PROCESS
• FIGURE 4. ORAL PROTEINS & PEPTIDES MARKET SIZE, 2023 VS 2030
• FIGURE 5. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 21. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. ORAL PROTEINS & PEPTIDES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 27. ORAL PROTEINS & PEPTIDES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ORAL PROTEINS & PEPTIDES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ORAL PROTEINS & PEPTIDES MARKET DYNAMICS
• TABLE 7. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COMBINATION INSULIN PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LONG-ACTING INSULIN ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RAPID-ACTING INSULIN ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RECOMBINANT HUMAN INSULIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CALCITONIN-BASED THERAPIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY VASOPRESSIN ANALOGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CAPSULE FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POWDER FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY TABLET FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE I & II CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POST-MARKET SURVEILLANCE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRECLINICAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CANCER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 52. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 53. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 55. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 56. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 59. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 62. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 63. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 64. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 65. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 66. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 69. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 70. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 71. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 72. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 73. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 76. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 77. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 78. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 79. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 80. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 82. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 83. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 84. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 85. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 86. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 87. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 88. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 91. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 92. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 93. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 94. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 95. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 96. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 99. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 100. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 101. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 102. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 103. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 106. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 107. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 108. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 109. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 110. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 113. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 114. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 115. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 116. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 117. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 118. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 119. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 120. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 121. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 122. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 123. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 124. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 127. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 128. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 129. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 130. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 131. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 134. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 135. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 136. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 137. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 138. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 141. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 142. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 143. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 144. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 145. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 146. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 148. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 149. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 150. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 151. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 152. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 153. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 154. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 155. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 156. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 157. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 158. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 159. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 160. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 161. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 162. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 163. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 164. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 165. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 166. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 167. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 168. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 169. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 170. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 171. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 172. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 173. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 174. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 175. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 176. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 177. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 178. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 179. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 180. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 181. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 182. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 183. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 184. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 185. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 186. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 187. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 188. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 189. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 190. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 191. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 192. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 193. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 194. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 195. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 196. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 197. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 198. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 199. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 200. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 201. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 202. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 203. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 204. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 205. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 206. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 207. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 208. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 209. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 210. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 211. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 212. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 213. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 214. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 215. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 216. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 217. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 218. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 219. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 220. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 221. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 222. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 223. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 224. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 225. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 226. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 227. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 228. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 229. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 230. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 231. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 232. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 233. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 234. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 235. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 236. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 237. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 238. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 239. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 240. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 241. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 242. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 243. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 244. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 245. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 246. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 247. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 248. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 249. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 250. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 251. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 252. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 253. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 254. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 255. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 256. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 257. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 258. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 259. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 260. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 261. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 262. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 263. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 264. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 265. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 266. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 267. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 268. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 269. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 270. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 271. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 272. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 273. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 274. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 275. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 276. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 277. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 278. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 279. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 280. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 281. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 282. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 283. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 284. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 285. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 286. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 287. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 288. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 289. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 290. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 291. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 292. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 293. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 294. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 295. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 296. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 297. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 298. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 299. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 300. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 301. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 302. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 303. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 304. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 305. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 306. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 307. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 308. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 309. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 310. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 311. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 312. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 313. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 314. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 315. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 316. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 317. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
• TABLE 318. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 319. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
• TABLE 320. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
• TABLE 321. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE,

The Oral Proteins & Peptides Market was valued at USD 6.10 billion in 2023 and is projected to grow to USD 6.89 billion in 2024, with a CAGR of 13.27%, reaching USD 14.60 billion by 2030.

Oral proteins and peptides have emerged as a focal point in the evolving landscape of therapeutics, offering transformative advantages in disease management and patient adherence. In recent years, significant advances in biotechnology and formulation science have paved the way for these molecules to transcend traditional administration barriers. There is an increasing emphasis on developing robust oral delivery systems that not only ensure bioavailability, but also enhance patient comfort and compliance. As research deepens and technology evolves, the market is witnessing a surge in interest from pharmaceutical developers, healthcare providers, and investors alike.

This comprehensive review details the current state of the market while also offering insights on future growth trajectories. It navigates through key trends, examines innovative formulation strategies, and evaluates the impact of regulatory frameworks on market expansion. The analysis is framed within an environment marked by rapid technological advancement and a global push for more effective, patient-centric therapies. This discussion is aimed at stakeholders who are known for their commitment to evidence-based decision-making and strategic market interventions. With evolving patient needs driving demand, the oral proteins and peptides market is set for disruptive breakthroughs that are poised to redefine treatment paradigms and optimize therapeutic outcomes.

From a strategic perspective, this document serves as an invaluable intellectual hub, offering data-backed insights and detailed qualitative analyses that help elucidate market behavior. The insights provided focus on integrating clinical advances and market strategies to address unmet medical needs. Ultimately, the synthesis of these insights sets the stage for a transformative journey, emphasizing the importance of aligning research, innovation, and commercialization activities in a tightly interconnected market.

Transformative Shifts in the Market Landscape and Their Strategic Implications

Over the past few years, the market for oral proteins and peptides has experienced transformative shifts, driven by rapid scientific breakthroughs and realignment of global healthcare priorities. Recent innovations in drug delivery systems have challenged the long-standing reliance on parenteral administration by introducing promising alternatives that effectively combine convenience with efficacy. This evolution is underpinned by a renewed focus on patient-centric approaches, advanced biotechnology, and strategic partnerships between research institutions and the pharmaceutical industry.

The advent of novel encapsulation techniques, improvements in peptide stability, and refinements in oral absorption enhancements are central to this transformation. Regulatory agencies are increasingly adapting their frameworks to accommodate breakthrough therapies, thereby accelerating approvals and fostering an environment that is receptive to innovation. In parallel with these technological advancements, market stakeholders have begun to reorient their strategies toward the development of integrated solutions that address both clinical requirements and economic sustainability. Decision-makers are now leveraging predictive analytics, big data, and risk-based monitoring to streamline research and development pipelines while minimizing time-to-market.

Additionally, the market has seen a significant realignment with respect to global investment flows, where emphasis is placed on targeting emerging therapeutic areas and underserved patient segments. As a result, traditional market players are compelled to rethink their operational frameworks and pursue dynamic, flexible business models. This shift is not merely an incremental improvement; it signifies a paradigm change that is redefining competitive strategies and forging new value propositions in clinical practice. In this environment, a forward-thinking approach, anchored in robust research and seamless execution, is essential to harnessing the benefits of these transformative changes.

Key Segmentation Insights Shaping Product Development and Market Strategy

A nuanced understanding of market segmentation underpins strategic planning and product development in the oral proteins and peptides space. The market is rigorously analyzed based on multiple dimensions, each yielding critical insights into its structure and growth potential. Firstly, product type segmentation distinguishes between Insulin-Based Proteins and Peptide Therapeutics. Further intricacies within this category reveal sub-segments such as Combination Insulin Products, Long-Acting Insulin Analogues, Rapid-Acting Insulin Analogues, and Recombinant Human Insulin, as well as segments corresponding to Calcitonin-Based Therapies, Glucagon-Like Peptide-1 Receptor Agonists, and Vasopressin Analogs. This detailed partitioning facilitates a deep dive into therapeutic efficacy, market penetration, and innovation trends.

The market is also segmented on the basis of formulation, where the importance of delivery format is underscored by the range of options available, such as Capsule Formulations, Liquid Formulations, Powder Formulations, and Tablet Formulations. These formats are continuously tested and optimized to improve patient compliance and clinical outcomes. In parallel, the development stage segmentation offers insights into the maturity level of therapeutics, categorized into Phase I & II Clinical Trials, Phase III Clinical Trials, Post-Market Surveillance, and Preclinical Studies. This segmentation not only highlights the research intensity but also aids in identifying the risk profile of pipeline products.

Application-based segmentation further refines the market perspective by focusing on specific therapeutic areas such as Cancer Treatment, Cardiovascular Diseases, Diabetes Management, and Hormonal Disorders. This approach ensures that each application area receives tailored strategies for market entry, regulatory compliance, and patient engagement. The segmentation based on end-user, which includes Home Care Settings, Hospitals & Clinics, Research Laboratories, and Specialty Clinics, plays a pivotal role in aligning product positioning to customer needs and operational realities. By integrating these various segmentation dimensions into a comprehensive analysis, stakeholders can better forecast market opportunities and address the complex interplay between clinical innovation and commercial viability.

Based on Product Type, market is studied across Insulin-Based Proteins and Peptide Therapeutics. The Insulin-Based Proteins is further studied across Combination Insulin Products, Long-Acting Insulin Analogues, Rapid-Acting Insulin Analogues, and Recombinant Human Insulin. The Peptide Therapeutics is further studied across Calcitonin-Based Therapies, Glucagon-Like Peptide-1 Receptor Agonists, and Vasopressin Analogs.

Based on Formulation, market is studied across Capsule Formulations, Liquid Formulations, Powder Formulations, and Tablet Formulations.

Based on Development Stage, market is studied across Phase I & II Clinical Trials, Phase III Clinical Trials, Post-Market Surveillance, and Preclinical Studies.

Based on Application, market is studied across Cancer Treatment, Cardiovascular Diseases, Diabetes Management, and Hormonal Disorders.

Based on End-User, market is studied across Home Care Settings, Hospitals & Clinics, Research Laboratories, and Specialty Clinics.

Key Regional Insights Illuminating Global Market Dynamics

The regional breakdown of the oral proteins and peptides market provides critical insight into localized trends and growth potentials. In the Americas, the market benefits from robust research ecosystems, substantial investment in biotechnology, and favorable regulatory environments. These factors create a fertile ground for rapid innovation and large-scale market adoption. Meanwhile, the combination of mature healthcare infrastructures and evolving patient needs in Europe, the Middle East, and Africa stimulates adoption of advanced therapeutic strategies. The region's diverse landscape supports both cutting-edge research and a gradual shift towards patient-focused therapy.

In the Asia-Pacific region, economic growth and expanding healthcare access are driving increased investments in pharmaceutical research and development. This dynamic span fosters an environment where emerging innovations in oral delivery systems are translated rapidly into clinical applications. The region is witnessing a growing enthusiasm towards integrating advanced therapeutic solutions into routine care, driven by rising healthcare awareness and proactive government policies. Each region, with its unique socio-economic and regulatory framework, influences the overall dynamics of the market. The interplay between regional strengths and market challenges provides a multi-faceted view of the global landscape, reinforcing the fact that geographical nuances are integral to strategic planning and market penetration efforts.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights Highlighting Industry Trailblazers and Innovators

The landscape of oral proteins and peptides is shaped by a network of industry-leading companies that are at the forefront of scientific and commercial innovation. Prominent players such as AbbVie Inc. and Amgen Inc. are renowned for their strong investment in research and a robust portfolio of advanced therapeutics. Companies like Amryt Pharma plc and Astellas Pharma Inc. leverage niche expertise to carve out significant market opportunities within specialized therapeutic areas.

Similarly, multinational corporations including AstraZeneca PLC and Boehringer Ingelheim International GmbH are redefining industry standards through strategic investments in R&D and partnerships that streamline the drug development process. Other innovators such as Catalent, Inc. and Entera Bio Ltd. by DNA Biomedical Solutions are noted for their state-of-the-art manufacturing capabilities and technological prowess that drive the efficient translation of research findings into market-ready products. Meanwhile, reputable names like F. Hoffmann-La Roche AG and Hunan Huateng Pharmaceutical Co., Ltd. by Tasly Capital bring in a wealth of global experience and a strong commitment to patient-centric solutions. Johnson & Johnson Services, Inc., Merck KGaA, and Novartis AG contribute to the competitive landscape through expansive research networks and consolidated market presence, while Novo Nordisk A/S and Oramed Pharmaceuticals Inc. push forward the frontier in treatment innovation. Emerging companies such as PeptiDream Inc., Pfizer, Inc., Protagonist Therapeutics, Inc., Proxima Concepts Limited, Rani Therapeutics, LLC, Sanofi S.A., Tarsa Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., and Zealand Pharma A/S complete the mosaic of global leaders whose collective drive for excellence and innovation has ushered in new paradigms in the oral proteins and peptides market.

These companies not only invest heavily in research and development but are also adept at navigating complex regulatory environments and logistical challenges. Their strategic initiatives range from aggressive expansion into emerging markets to pioneering partnerships that leverage complementary expertise, thus ensuring a steady pipeline of innovative products designed for higher efficacy and improved patient outcomes.

The report delves into recent significant developments in the Oral Proteins & Peptides Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Amryt Pharma plc, Astellas Pharma Inc., AstraZeneca PLC, Biocon Limited, Boehringer Ingelheim International GmbH, Catalent, Inc., Entera Bio Ltd. by DNA Biomedical Solutions, F. Hoffmann-La Roche AG, Hunan Huateng Pharmaceutical Co., Ltd. by Tasly Capital, Johnson & Johnson Services, Inc., Merck KGaA, Novartis AG, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., PeptiDream Inc., Pfizer, Inc., Protagonist Therapeutics, Inc., Proxima Concepts Limited, Rani Therapeutics, LLC, Sanofi S.A., Tarsa Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., and Zealand Pharma A/S. Actionable Recommendations for Industry Leaders to Capitalize on Market Opportunities

Industry leaders are encouraged to adopt a proactive and integrated approach to capturing market opportunities in the evolving oral proteins and peptides space. It is essential to intensify investments in advanced drug delivery systems as part of dedicated R&D initiatives, particularly focusing on enhancing bioavailability and patient compliance. Leaders should re-assess current portfolio strategies with a view toward diversification across multiple segmentation dimensions, such as product type, formulation, development stage, application, and end-user. This holistic strategy ensures that resources are optimally allocated towards both innovation and market expansion.

Embracing digital transformation tools can further streamline research and market analysis, enabling predictive modeling and more precise forecasting of clinical outcomes and market trends. Companies should consider collaborating with digital health startups and leveraging big data analytics to inform product development decisions and improve operational efficiencies. Additionally, pursuing strategic alliances and partnerships, whether through mergers, acquisitions, or research collaborations, could significantly mitigate risk while enhancing the flow of technological innovation. This approach not only broadens the scope for breakthrough research but also shortens the time to market for novel therapeutics.

In parallel, market leaders must remain agile in navigating evolving regulatory landscapes. A continuous dialogue with regulatory bodies, coupled with proactive compliance and robust quality control systems, will be critical to overcoming barriers and expediting market entry. In this highly competitive environment, it is also advisable to invest in building a flexible yet resilient supply chain to support rapid scaling and distribution of new products. Ultimately, adopting an integrated strategy that emphasizes innovation, collaboration, and operational excellence will enhance a company's ability to capitalize on the emerging opportunities in the oral proteins and peptides market.

Conclusion: Harnessing Innovation and Strategic Alliances to Drive Future Growth

In summary, the oral proteins and peptides market is undergoing a period of significant transformation. In light of rapid technological progress, shifting consumer expectations, and dynamic regulatory environments, the market presents promising growth trajectories and an array of opportunities for stakeholders worldwide. Detailed analysis indicates that diversified segmentation - spanning from product types and formulations to clinical trial phases and application domains - provides a comprehensive framework for understanding market intricacies. Regional nuances further corroborate that tailored strategies are essential to address localized challenges and leverage unique market strengths.

The insights outlined in this summary reflect a blend of cutting-edge research and real-world strategic initiatives. They underscore the importance of innovation, improved clinical practices, and adaptive operational models in overcoming market uncertainties. As technological advancements continue to push the boundaries of what is clinically possible, the integration of these insights into business strategy is key to achieving sustained growth and competitive advantage. The journey forward will depend on the ability of industry leaders to forge strategic alliances, embrace new technologies, and continuously adapt to an evolving market landscape.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of chronic diseases demanding innovative oral protein therapeutics
    • 5.1.1.2. Growing need for oral protein and peptide supplements with growing nutritional awareness
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns associated with significant side effects
  • 5.1.3. Opportunities
    • 5.1.3.1. Collaborative partnerships between pharma and biotech companies for advancing oral protein therapies
    • 5.1.3.2. Emerging focus on the development of macrocyclic peptides
  • 5.1.4. Challenges
    • 5.1.4.1. Regulatory hurdles affecting the approval processes for new oral protein-based therapeutics globally
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product Type: Increasing need for peptide therapeutics targeting bone metabolism disorders and Type 2 diabetes
  • 5.2.2. Formulation: Growing preferences for capsule formulations owing to their ease of administration and ability to protect sensitive biological compounds
  • 5.2.3. Development Stage: Exploring diversities across developmental stages in oral proteins & peptides
  • 5.2.4. Application: Growing demand for oral proteins and peptides in cancer treatment for enhancing patient compliance
  • 5.2.5. End-User: Rising consumer preference for oral proteins and peptides in home care settings
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Oral Proteins & Peptides Market, by Product Type

• 6.1. Introduction
• 6.2. Insulin-Based Proteins
  • 6.2.1. Combination Insulin Products
  • 6.2.2. Long-Acting Insulin Analogues
  • 6.2.3. Rapid-Acting Insulin Analogues
  • 6.2.4. Recombinant Human Insulin
• 6.3. Peptide Therapeutics
  • 6.3.1. Calcitonin-Based Therapies
  • 6.3.2. Glucagon-Like Peptide-1 Receptor Agonists
  • 6.3.3. Vasopressin Analogs

7. Oral Proteins & Peptides Market, by Formulation

• 7.1. Introduction
• 7.2. Capsule Formulations
• 7.3. Liquid Formulations
• 7.4. Powder Formulations
• 7.5. Tablet Formulations

8. Oral Proteins & Peptides Market, by Development Stage

• 8.1. Introduction
• 8.2. Phase I & II Clinical Trials
• 8.3. Phase III Clinical Trials
• 8.4. Post-Market Surveillance
• 8.5. Preclinical Studies

9. Oral Proteins & Peptides Market, by Application

• 9.1. Introduction
• 9.2. Cancer Treatment
• 9.3. Cardiovascular Diseases
• 9.4. Diabetes Management
• 9.5. Hormonal Disorders

10. Oral Proteins & Peptides Market, by End-User

• 10.1. Introduction
• 10.2. Home Care Settings
• 10.3. Hospitals & Clinics
• 10.4. Research Laboratories
• 10.5. Specialty Clinics

11. Americas Oral Proteins & Peptides Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Oral Proteins & Peptides Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Oral Proteins & Peptides Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. CordenPharma's EUR 900 million investment aims to transform peptide manufacturing across the US and Europe
  • 14.3.2. Glanbia Nutritionals revolutionizes collagen supplementation with the launch of fast-absorbing Collameta
  • 14.3.3. Incyte expands inflammation portfolio with Escient acquisition, introducing novel oral MRGPR antagonists
  • 14.3.4. Johnson & Johnson achieves promising phase II results with JNJ-2113, a groundbreaking oral peptide for plaque psoriasis
  • 14.3.5. Orbis Medicines revolutionizes oral peptide drug delivery with EUR 26 million funding to enhance patient experience
  • 14.3.6. Novartis acquisition of MorphoSys AG strengthens oncology pipeline with focus on oral proteins and peptides
  • 14.3.7. Innovative partnership between Vivtex and AI Proteins aims to revolutionize oral therapies for inflammation
• 14.4. Strategy Analysis & Recommendation
  • 14.4.1. AstraZeneca PLC
  • 14.4.2. Johnson & Johnson Services, Inc.
  • 14.4.3. Novo Nordisk A/S
  • 14.4.4. Novartis AG

Companies Mentioned

• 1. AbbVie Inc.
• 2. Amgen Inc.
• 3. Amryt Pharma plc
• 4. Astellas Pharma Inc.
• 5. AstraZeneca PLC
• 6. Biocon Limited
• 7. Boehringer Ingelheim International GmbH
• 8. Catalent, Inc.
• 9. Entera Bio Ltd. by DNA Biomedical Solutions
• 10. F. Hoffmann-La Roche AG
• 11. Hunan Huateng Pharmaceutical Co., Ltd. by Tasly Capital
• 12. Johnson & Johnson Services, Inc.
• 13. Merck KGaA
• 14. Novartis AG
• 15. Novo Nordisk A/S
• 16. Oramed Pharmaceuticals Inc.
• 17. PeptiDream Inc.
• 18. Pfizer, Inc.
• 19. Protagonist Therapeutics, Inc.
• 20. Proxima Concepts Limited
• 21. Rani Therapeutics, LLC
• 22. Sanofi S.A.
• 23. Tarsa Therapeutics, Inc.
• 24. Teva Pharmaceutical Industries Ltd.
• 25. Zealand Pharma A/S